focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Pin to quick picksAlliance Pharma Share News (APH)

Share Price Information for Alliance Pharma (APH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 35.00
Bid: 35.00
Ask: 35.40
Change: 0.00 (0.00%)
Spread: 0.40 (1.143%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 35.00
APH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Applied Graphene launches strategic review

Wed, 23rd Nov 2022 11:14

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Europa Metals Ltd, up 42% at 3.98 pence, 12-month range 2.5p-5.3p. The lead, zinc and silver mine developer enters into an option agreement with Denarius Metals Corp, granting Denarius the right to acquire up to 80% of its wholly-owned Spanish subsidiary, Europa Metals Iberia. The subsidiary holds the Toral project in northwest Spain. Should shareholders approve the deal, Europa would secure an initial USD4.0 million for the Toral project, with a potential future cash payment of USD2.0 million. The first amount would give Denarius a 51% stake and the second an additional 29%. Europa Metals also conditionally raises GBP580,000 via subscription of 12.9 million new shares at issue price of 4.5p, a 61% premium to the closing price of 2.8p on Tuesday.

----------

Zanaga Iron Ore Co Ltd, up 23% at 4.1p, 12-month range 1.7p-5.2p. The part owner of the Zanaga iron ore project in the Republic of Congo reaches an agreement to buy Glencore Projects' controlling shareholding in the project. This would be enacted via the purchase of Glencore Projects' 50% plus one share interest in Jumelles - an entity which indirectly holds the benefit of the ZIO project's mining license - in exchange for the issue of 286.3 million new shares to Glencore Projects. This would represent a shareholding of 48% in ZIOC. "The acquisition is value accretive to shareholders and increases effective equity ownership of the project by existing shareholders, enhancing their look-through ownership of the project and securing control of the project without paying any premium for such interest," says Chair Clifford Elphick. Glencore Projects is a subsidiary of Swiss-based miner Glencore PLC.

----------

AIM - LOSERS

----------

Alliance Pharma PLC, down 30% at 42.46p, 12-month range 41.28p-122p. The distributor of consumer healthcare brands and prescription medicines says some larger orders in the fourth quarter of 2022 will not materialise. This is due to a slower-than-expected recovery in the business-to-business market, as well as a hit to sales from "a one-off destocking effect". It now expects annual revenue to be at least GBP170 million, with underlying pretax profit of at least GBP30 million. This is compared with 2021's revenue of GBP163.2 million and underlying pretax profit of GBP42.2 million. CEO Peter Butterfield will take time off from the business "for personal reasons", and return in January. Chief Financial Officer Andrew Franklin will assume his responsibilities in the meantime.

----------

Applied Graphene Materials PLC, down 39% at 3p, 12-month range 3p-28.5p. The graphene developer begins strategic review in light of its "funding position and...the unfavourable conditions in small-cap equity markets". The options pursued may include raising funds from a specialist debt provider or strategic investor, selling its trade and assets, or selling shares in its main operating subsidiary. It also decides to begin statutory redundancy consultations with its employees, to protect its financial position in case the review does not reach "a satisfactory conclusion".

----------

By Elizabeth Winter; elizabethwinter@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
29 Jun 2021 14:14

EXECUTIVE CHANGES: Greencare Capital chair retires after May promotion

EXECUTIVE CHANGES: Greencare Capital chair retires after May promotion

Read more
3 Jun 2021 15:50

UK dividends calendar - next 7 days

UK dividends calendar - next 7 days

Read more
19 May 2021 19:33

TRADING UPDATES: Young's mulls asset sale; Ceres gets China investment

TRADING UPDATES: Young's mulls asset sale; Ceres gets China investment

Read more
19 May 2021 09:00

Strong trading continues in new year for Alliance Pharma

(Sharecast News) - Alliance Pharma updated the market on its trading on Wednesday, reiterating that the year had started well, adding that it was continuing to see some "strong performances" from its key brands.

Read more
12 May 2021 16:04

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
15 Apr 2021 19:37

TRADING UPDATES: HSBC announces redemption of US dollar securities

TRADING UPDATES: HSBC announces redemption of US dollar securities

Read more
29 Mar 2021 09:36

BROKER RATINGS: Morgan Stanley upgrades BT to Overweight

BROKER RATINGS: Morgan Stanley upgrades BT to Overweight

Read more
24 Mar 2021 10:11

Indivior revamps board after accord with biggest shareholder Scopia

Indivior revamps board after accord with biggest shareholder Scopia

Read more
23 Mar 2021 11:27

TRADING UPDATES: McColl's decides against payout; Luceco profit surges

TRADING UPDATES: McColl's decides against payout; Luceco profit surges

Read more
23 Mar 2021 11:01

Consumer brands underpin Alliance Pharma performance

(Sharecast News) - Alliance Pharma reported a 4% fall in statutory revenue in its preliminary results on Tuesday, to £129.8m, although it said performance from its consumer healthcare brands was "strong", with that division now accounting for more than two thirds of group see-through revenues.

Read more
16 Mar 2021 15:53

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
20 Jan 2021 17:40

LONDON TRADING UPDATES: Alliance Pharma 2020 Revenue Slips By 5%

LONDON TRADING UPDATES: Alliance Pharma 2020 Revenue Slips By 5%

Read more
31 Dec 2020 17:12

UK Dividends Calendar - Next 7 Days

UK Dividends Calendar - Next 7 Days

Read more
29 Dec 2020 15:58

IN BRIEF: Alliance Pharma Completes US Consumer Healthcare Firm Buy

IN BRIEF: Alliance Pharma Completes US Consumer Healthcare Firm Buy

Read more
10 Dec 2020 15:55

UK Dividends Calendar - Next 7 Days

UK Dividends Calendar - Next 7 Days

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.